Resolvin D1 is from a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA) and docosahexaenoic (DHA)(1), it is an anti-inflammatory and promotes the resolution of the inflammatory response back to a non-inflamed state.2 RvD1 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase. It reduces human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC50 values of ~30 nM. It exhibits a dose-dependent reduction in leukocyte infiltration in a murine model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.
|Identification (Mass Spectrometry - ESI)||M-H+: 375.3||M-H+: 375.9|
|Purity (HPLC)||≥ 95%||99.2%Retention time actual: 21.10 min|
|UV/Visible Spectrum||Solvent: ethanolλmax: 302 nmAbs: 0.6640Conc.: 100.00 mg/ml||λmax: 302 nmAbs: 0.6880Conc.: 103612.80 µg/ml|
|λmax||302 nm||302 nm|
HPLC Conditions: Column: C18, 5µ, 4.6 X 250 mm; Mob Phase: Methanol: Water: Acetic acid (60: 40: 0.1); Flow Rate: 1.00 ml/min; Detector UV: 302 nm
See how others have used Resolvin D1 (CAS 872993-05-0). Click on the entry to view the PubMed entry .
PMID: 34570918 | Resolvin D1 prevents cadmium chloride-induced memory loss and hippocampal damage in rats by activation/upregulation of PTEN-induced suppression of PI3K/Akt/mTOR signaling pathway. | Shati, AA. et al. 2022. Clin Exp Pharmacol Physiol. 49: 275-290.